FlowCardia, Inc. Appoints Deborah DeFilippo CFO - Gilde Healthcare

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

18. Juni 2008

SUNNYVALE, Calif., June 18, 2008 — FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer. Ms. DeFilippo comes to FlowCardia with over 19 years of experience in Medical Devices. 

Most recently, Ms. DeFilippo served as Chief Financial Officer and Vice President, Business Development for the Guidant Cardiac Surgery business. Prior to that, she held a variety of executive positions at Guidant divisions as well as the Corporate Office of Guidant. Earlier, Ms. DeFilippo was the Director of Finance and Information Systems at Devices for Vascular Intervention prior to DVI’s acquisition by Guidant. Ms. DeFilippo holds a B.A. from Stanford University.

“We are tremendously pleased that Deborah will be joining FlowCardia. She is not only a very experienced financial executive but has also overseen such functions as Strategic Planning, Information Systems and Business Reengineering during her time with Guidant,”

said Wick Goodspeed, President and CEO of FlowCardia.

“Deborah will be a great addition to our management team and a substantial contributor to our sales growth and transition to profitability over the next few years.”

“I’m thrilled to be returning to the medical device field and joining FlowCardia at such an exciting time,”

said Ms. DeFilippo.

“FlowCardia is growing rapidly in its first year of commercialization and I am enthusiastic about the opportunity to help the Company become the leading CTO Device Company in the world.”

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture endovascular CTO recanalization systems. Additional information is available on the Company’s Web Site at www.flowcardia.com.

CONTACT
Mark Page
Sr. Director Marketing
FlowCardia, Inc.
T: 408-617-0352 ext. 301

SOURCE
FlowCardia, Inc.

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
16. Juli 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5. Juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21. Mai 2024